It may also support the gut-brain axis by influencing neurochemical pathways and promoting communication between the gastrointestinal tract and central nervous system (CNS)
Drug exposure The study cohort consisted of new users of GLP-1RAs (dulaglutide, exenatide, liraglutide, lixisenatide or semaglutide), SGLT2 inhibitors (canagliflozin, dapagliflozin or empagliflozin), metformin and other second- or third-line glucose-lowering drugs (thiazolidinediones, dipeptidyl peptidase-4 inhibitors, sulfonylureas, meglitinides, -glucosidase inhibitors, insulin or a combination of glucose-lowering drugs)
Gastrointestinal adverse events represent a notable concern in individuals receiving GLP-1 RAs, potentially impacting treatment adherence and patient satisfaction
Research and Clinical Evidence Tirzepatide has become one of the most extensively studied metabolic peptides in recent years
Our Clinicals
Identify Semaglutides HSA Eligibility Requirements Semaglutide, available under brand names such as Ozempic and Wegovy, is an FDA-approved medication primarily utilized for managing type 2 diabetes and facilitating weight loss